



Approved for use through 03/31/2007. OMB/SB/21 (09-06)  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/594,990
Filing Date	September 29, 2006
First Named Inventor	Manuel WORCEL
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	0102258.00375US2

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	WILMER CUTLER PICKERING HALE AND DORR LLP	
Signature	<i>Belinda Lew</i>	
Printed name	Belinda Lew	
Date	JANUARY 29, 2007	Reg. No. 53,212



Docket No.: 0102258.00375US2  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Manuel WORCEL                      Confirmation No.: @@@@  
Application No.: 10/594,990                      Art Unit: N/A  
Filed: September 29, 2006                      Examiner: Not Yet Assigned  
Title: METHOD FOR TREATING BLOOD DISORDERS WITH NITRIC  
OXIDE DONOR COMPOUNDS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Dear Sir:

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No fee is required.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: *JANUARY 29, 2007*

Belinda Lew  
Registration No.: 53,212

Wilmer Cutler Pickering Hale and Dorr LLP  
1875 Pennsylvania Avenue, NW  
Washington, DC 20006  
(202) 663-6000 (telephone)  
(202) 663-6363 (facsimile)



10594990 - GAU: 1612

PTO/SB/08A/B (09-06)  
Approved for use through 03/12/2007. CMB 6651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Copyright Clearance Center (CCC) Copyright Licensing Agreement, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/594,990
				Filing Date	September 29, 2006
				First Named Inventor	Manuel WORCEL
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	0102258.00375US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Whom Relevant Passages or Relevant Figures Appear
	AA*	US-20060182815-A1	08-17-2006	Gladwin et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>2</sup> -Number <sup>2</sup> -Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Whom Relevant Passages or Relevant Figures Appear
	BA	WO-2005/004884-A2	01-20-2005	M. Gladwin	
	BB	WO-2005/007173-A1	01-27-2005	M. Gladwin	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. \* Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Error Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	CA	Bryan et al. "Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues" Nature Chemical Biology, Advanced Online Publication, pages 1-8 (2005).			
	CB	Cosby et al. "Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation" Nature Medicine, Vol. 9, No. 12, pages 1498-1505 (2003).			
	CC	Dejam et al. "Emerging role of nitrite in human biology" Blood Cells, Molecules, and Diseases, Vol. 32, pages 423-429 (2004).			
	CD	Diaz et al. "Effect of graded levels of dietary nitrite on pulmonary hypertension in broiler chickens and dilatory cardiomyopathy in turkey poults" Avian Pathology, Vol. 24, pages 109-120 (1995).			
	CE	Doyle et al. "Kinetics and Mechanism of the Oxidation of Human Deoxyhemoglobin by Nitrites" The Journal of Biological Chemistry, Vol. 236, No. 23, pages 12393-12396 (1981).			
	CF	Duranski et al. "Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver" The Journal of Clinical Investigation, pages 1-9 (2005).			
	CG	Gabel et al. "Decreased intracellular pH is not due to increased H <sup>+</sup> extrusion in preconditioned rat hearts" Am. J. Physiol. Vol. 273, pages H2257-H2262 (1997).			
	CH	Gladwin et al. "Haldane, hot dogs, halitosis, and hypoxic vasodilation: the emerging biology of the nitrite anion" J. Clin. Invest., Vol. 113, pages 19-21 (2004).			
	CI	Gladwin et al. "Role of circulating nitrite and S-nitrosohemoglobin in the regulation of regional blood flow in humans" Vol. 97, No. 21, pages 11482-11487 (2000).			
	CJ	Gruetter et al. "Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amylin nitrate" Cancer J. Physiol. Pharmacol., Vol. 59, pages 150-156 (1981).			
	CK	Hunter et al. "Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator" Nature Medicine, Vol. 10, No. 10, pages 1122-1127 (2004).			
	CL	Johnson et al. "Cardioprotective Effects of Acidified Sodium Nitrite in Myocardial Ischemia with			

Examiner Signature	Date Considered
--------------------	-----------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /S.K./  
BEST AVAILABLE COPY



10594990 - GAU: 1612

Approved for use through 03/31/2007. OMB 0551-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/594,990		
		Filing Date	September 29, 2006		
		First Named Inventor	Manuel WORCEL		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	0102258.00375US2

		Reperfusion" The Journal of Pharmacology and Experimental Therapeutics" Vol. 252, No. 1, pages 35-41 (1989).	
CM		Johnson et al. "Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion" Critical Care Medicine, Vol. 19, No. 2, pages 244-251 (1991).	
CN		Kelm et al. "Serum nitrite sensitively reflects endothelial NO formation in human forearm vasculature: evidence for biochemical assessment of the endothelial L-arginine-NO pathway" Cardiovascular Research, Vol. 4, pages 765-772 (1999).	
CO		Lauer et al. "Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action" PNAS, Vol. 98, No. 22, pages 12814-12819 (2001).	
CP		Lefer et al. "Cardiac venous endothelial dysfunction after myocardial ischemia and reperfusion in dogs" Am. J. Physiol., Vol. 263, No. 3, pages H850-H856 (1992).	
CQ		Lundberg et al. "NO Generation From Nitrite and Its Role in Vascular Control" Arterioscler Thromb Vasc Biol., Vol. 25, pages 915-922 (2005).	
CR		Modin et al. "Nitrite-derived nitric oxide: a possible mediator of 'acidic-metabolic' vasodilation" Acta Physiol Scand., Vol. 171, pages 9-16 (2001).	
CS		Moulds et al. "A Comparison of the Effects of Hydralazine, Diazoxide, Sodium Nitrite and Sodium Nitroprusside on Human Isolated Arteries and Veins" J. Clin. Pharmac., Vol. 1, pages 57-61 (1981).	
CT		Pluta et al. "Nitrite Infusions to Prevent Delayed Cerebral Vasospasm in a Primate Model of Subarachnoid Hemorrhage" JAMA, Vol. 293, No. 12, pages 1477-1484 (2005).	
CU		Rassaf et al. "Evidence for in vivo transport of bioactive nitric oxide in human plasma" The Journal of Clinical Investigation, Vol. 109, No. 9, pages 1241-1248 (2002).	
CV		Schechter et al. "NO Solutions?" The Journal of Clinical Investigation, Vol. 109, No. 9, pages 1149-1151 (2002).	
CW		Shen et al. "Effects of EGB 761 on nitric oxide and oxygen free radicals, myocardial damage and arrhythmia in ischemia-reperfusion injury in vivo" Biochimica et Biophysica Acta 1406, pages 228-236 (1998).	
CX		Shirasaki et al. "Endothelium removal augments vasodilation by sodium nitroprusside and sodium nitrite" European Journal of Pharmacology, Vol. 114, pages 93-96 (1985).	
CY		Tiravanti et al. "Nitrosyl-Heme Complexes Are Formed in the Ischemic Heart", The Journal of Biological Chemistry, Vol. 279, No. 12, pages 11065-11073 (2004).	
CZ		Uchida et al. "Nitric Oxide Donating Compounds Inhibit HC1-Induced Gastric Mucosal Lesions Mainly via Prostaglandin" Jpn. J. Pharmacol., Vol. 85, pages 133-138 (2001).	
CA1		Wanstall et al. "Responses to vasodilator drugs on pulmonary artery preparations from pulmonary hypertensive rats" Br. J. Pharmacol., Vol. 105, pages 152-158 (1992).	
CB1		Webb et al. "Inorganic Nitrite: Protector Against Ischaemia Reperfusion Injury in the Heart?" Br. J. Pharmacol. (2003)	
CC1		Webb et al. "Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage" PNAS, Vol. 101, No. 37, pages 13683-13688 (2004).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Sriram Kasturi/	Date Considered	10/18/2008
--------------------	------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.K./  
BEST AVAILABLE COPY